Richard Vosser
Stock Analyst at JP Morgan
(2.06)
# 2,990
Out of 5,147 analysts
17
Total ratings
66.67%
Success rate
1.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Vosser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk | Downgrades: Neutral | n/a | $37.45 | - | 8 | Feb 24, 2026 | |
| MOLN Molecular Partners AG | Maintains: Neutral | $4 → $3.75 | $5.02 | -25.34% | 3 | Dec 8, 2025 | |
| GRFS Grifols | Maintains: Neutral | $10 | $9.10 | +9.89% | 1 | Dec 8, 2025 | |
| SNY Sanofi | Downgrades: Neutral | n/a | $48.66 | - | 4 | Dec 8, 2025 | |
| NVS Novartis AG | Upgrades: Overweight | n/a | $168.62 | - | 1 | Dec 8, 2025 |
Novo Nordisk
Feb 24, 2026
Downgrades: Neutral
Price Target: n/a
Current: $37.45
Upside: -
Molecular Partners AG
Dec 8, 2025
Maintains: Neutral
Price Target: $4 → $3.75
Current: $5.02
Upside: -25.34%
Grifols
Dec 8, 2025
Maintains: Neutral
Price Target: $10
Current: $9.10
Upside: +9.89%
Sanofi
Dec 8, 2025
Downgrades: Neutral
Price Target: n/a
Current: $48.66
Upside: -
Novartis AG
Dec 8, 2025
Upgrades: Overweight
Price Target: n/a
Current: $168.62
Upside: -